Addex Therapeutics (NASDAQ:ADXN) reported a CHF 1.1 million operating loss for the first half of 2026, compared with CHF 1.3 million a year earlier, as reduced outsourced research and development spending on its GABAB positive allosteric modulator, or PAM, program lowered expenses. Chief Executive Officer Tim Dyer said the company also raised $2.8 million through […]

Orbit Garant Drilling (TSE:OGD) reported record quarterly and annual revenue for fiscal 2026 as drilling activity increased in Canada, Chile and Guyana, though higher operating costs, lower efficiency and ramp-up expenses on new contracts pressured profitability. Fourth-quarter revenue rose 21.3% year over year to C$57.2 million, while full-year revenue increased 7.5% to a record C$203.2 […]